Research programme: neurological disorder therapeutics - Aequus Pharmaceuticals/CannaRoyalty

Drug Profile

Research programme: neurological disorder therapeutics - Aequus Pharmaceuticals/CannaRoyalty

Alternative Names: Cannabis-based therapies - Aequus Pharmaceuticals/CannaRoyalty

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aequus Pharmaceuticals
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurological disorders

Most Recent Events

  • 11 Jan 2018 Aequus Pharmaceuticals and CannaRoyalty agree to co-promote and co-develop cannabis-based therapies in Canada for Neurological disorders
  • 11 Jan 2018 Early research in Neurological disorders in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top